Michele Anderson, Univ. of Minnesota, Minneapolis, MN, United States
Slide Session 35, Paper B-306 (summary available)
C. difficile Rate Nearly Double Since 2001
The incidence of C. difficile infections in hospitals in the United States nearly doubled from 2001 to 2010.
Kelly Daniels, The Univ. of Texas at Austin, Austin, TX, United States
Slide Session 38, Paper K-327 (summary available)
Treatment Helps Prevent Recurrence of C. difficile
In patients who had previously been diagnosed with C. difficile infection and also required antibiotic treatment for other conditions, the addition of oral vancomycin to the necessary antibiotic treatment helped reduce the recurrence of C. difficile infection.
Alex Carignan, Universite de Sherbrooke, Sherbrooke, QC, Canada
Slide Session 38, Paper K-334
Dosages Equally Effective for C. difficile
There appears to be little difference in the effectiveness of low-dose versus high-dose oral vancomycin for the treatment of C. difficile infections in hospitals. Use of low-dose oral vancomycin can potentially decrease treatment costs.
Philip Chung, Albert Einstein Coll. of Med., Bronx, NY, United States
Slide Session 38, Paper K-335 (summary available)
WEDNESDAY, September 11, 2013
Anti-Infective Therapy in the 21st Century: Target the Host!
Since the discovery of sulfonamides, the goal of anti-infective therapy has been to kill the pathogen. However, recent science indicates that the host response to the pathogen profoundly influences the clinical course and outcome of infections. This symposium will review cutting edge approaches to find new ways to treat infections, modulate host response to the pathogen, a
|Contact: Garth Hogan|
American Society for Microbiology